Medication-related problems identified by community pharmacists: a descriptive case study of two Australian populations

References

• Ernst FR, Grizzle AJDrug-related morbidity and mortality: updating the cost-of-illness modelJ Am Pharm Assoc2001412192199 1:STN:280:DC%2BD3M3mvFOhtA%3D%3D 10.1016/s1086-5802(16)31229-3
   Google Scholar
• van Mil F, Horvat N, Westerlund T, Richling I. PCNE Classification for drug related problems V9.1 Zuidlaren: PCNE; 2020 [cited: 18 January 2023]. Available from: https://www.pcne.org/upload/files/417_PCNE_classification_V9-1_final.pdf.
   Google Scholar
• Strand LM, Morley PC, Cipolle RJ, Ramsey R, Lamsam GDDrug-related problems: their structure and functionDICP1990241110931097 1:STN:280:DyaK3M7ht1Wluw%3D%3D 10.1177/106002809002401114 2275235
   PubMedGoogle Scholar
• Al Hamid A, Ghaleb M, Aljadhey H, Aslanpour ZA systematic review of hospitalization resulting from medicine-related problems in adult patientsBIt J Clin Pharmacol2014782202217 10.1111/bcp.12293
   PubMed Web of Science ®Google Scholar
• Panagioti M, Khan K, Keers RN, Abuzour A, Phipps D, Kontopantelis E, et al.Prevalence, severity, and nature of preventable patient harm across medical care settings: systematic review and meta-analysisBMJ2019366 10.1136/bmj.l4185 31315828 6939648
   PubMedGoogle Scholar
• Lim R, Ellett LMK, Semple S, Roughead EEThe extent of medication-related hospital admissions in Australia: a review from 1988 to 2021Drug Saf2022453249257 10.1007/s40264-021-01144-1 35089582 8933367
   PubMed Web of Science ®Google Scholar
• Dalton K, Byrne SRole of the pharmacist in reducing healthcare costs: current insightsIntegr Pharm Res Pract201763746 10.2147/iprp.S108047 29354549 5774321
   PubMed Web of Science ®Google Scholar
• Griese-Mammen N, Hersberger KE, Messerli M, Leikola S, Horvat N, van Mil JWF, et al.PCNE definition of medication review: reaching agreementInt J Clin Pharm201840511991208 10.1007/s11096-018-0696-7 30073611
   PubMed Web of Science ®Google Scholar
• Hepler CD, Strand LMOpportunities and responsibilities in pharmaceutical careAm J Hosp Pharm1990473533543 1:STN:280:DyaK3c7ps1Sgsw%3D%3D 10.1093/ajhp/47.3.533 2316538
   PubMedGoogle Scholar
• Al-babtain B, Cheema E, Hadi MAImpact of community-pharmacist-led medication review programmes on patient outcomes: a systematic review and meta-analysis of randomised controlled trialsRes Social Adm Pharm202118425592568 10.1016/j.sapharm.2021.04.022 33965357
   PubMed Web of Science ®Google Scholar
• Jokanovic N, Tan EC, Sudhakaran S, Kirkpatrick CM, Dooley MJ, Ryan-Atwood TE, et al.Pharmacist-led medication review in community settings: an overview of systematic reviewsRes Social Adm Pharm2017134661685 10.1016/j.sapharm.2016.08.005 27665364
   PubMed Web of Science ®Google Scholar
• Bulajeva A, Labberton L, Leikola S, Pohjanoksa-Mäntylä M, Geurts M, De Gier J, et al.Medication review practices in European countriesRes Social Adm Pharm2014105731740 1:STN:280:DC%2BC2crmslKgsg%3D%3D 10.1016/j.sapharm.2014.02.005 24661800
   PubMed Web of Science ®Google Scholar
• Ontario Ministry of Health. MedsCheck General Information Toronto: Ontario Ministry of Health; 2022 [cited: 1 October 2022]. Available from: https://www.health.gov.on.ca/en/pro/programs/drugs/medscheck/faq_original.aspx#30.
   Google Scholar
• Stewart D, Whittlesea C, Dhital R, Newbould L, McCambridge JCommunity pharmacist led medication reviews in the UK: a scoping review of the medicines use review and the new medicine service literaturesRes Social Adm Pharm2020162111122 10.1016/j.sapharm.2019.04.010 31085141
   PubMed Web of Science ®Google Scholar
• Viswanathan M, Kahwati LC, Golin CE, Blalock SJ, Coker-Schwimmer E, Posey R, et al.Medication therapy management interventions in outpatient settings: a systematic review and meta-analysisJAMA Intern Med201517517687 10.1001/jamainternmed.2014.5841 25401788
   PubMed Web of Science ®Google Scholar
• Pharmacy Programs Administrator. MedsCheck and Diabetes MedsCheck. Melbourne: Pharmacy Programs Administrator; 2022 [cited: 13 January 2023]. Available from: https://www.ppaonline.com.au/programs/medication-management-programs/medscheck-and-diabetes-medscheck.
   Google Scholar
• Pharmacy Programs Administrator. Home Medicines Review Melbourne: Pharmacy Programs Administrator; 2022 [cited: 18 January 2023]. Available from: https://www.ppaonline.com.au/programs/medication-management-programs/home-medicines-review.
   Google Scholar
• Pharmacy Programs Administrator. Residential Medication Management Review and Quality Use of Medicines Melbourne: Pharmacy Programs Administrator; 2022 [cited: 18 January 2023]. Available from: https://www.ppaonline.com.au/programs/medication-management-programs/residential-medication-management-review-and-quality-use-of-medicines.
   Google Scholar
• Page A, Hyde Z, Smith K, Etherton-Beer C, Atkinson DN, Flicker L, et al.Potentially suboptimal prescribing of medicines for older Aboriginal Australians in remote areasMed J Aust20192113119125 10.5694/mja2.50226 31187902
   PubMed Web of Science ®Google Scholar
• Hamrosi K, Taylor SJ, Aslani PIssues with prescribed medications in Aboriginal communities: aboriginal health workers' perspectivesRural Remote Health200662113 10.22605/RRH557
   Google Scholar
• Kowanko I, Crespigny Cd, Murray H, Groenkjaer M, Emden CBetter medication management for Aboriginal people with mental health disorders: a survey of providersAust J Rural Health2004126253257 10.1111/j.1440-1854.2004.00625.x 15615578
   PubMedGoogle Scholar
• Swain LS, Barclay LExploration of aboriginal and Torres Strait islander perspectives of Home medicines reviewRural Remote Health20151516476 10.22605/RRH3009
   Web of Science ®Google Scholar
• World Health Organization. Management of physical health conditions in adults with severe mental disorders (WHO Guidelines) Geneva: World Health Organization; 2018 [cited: 30 March 2022]. Available from: https://www.who.int/publications/i/item/978-92-4-155038-3.
   Google Scholar
• Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al.Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysisLancet Psychiatry2020716477 10.1016/s2215-0366(19)30416-x 31860457 7029416
   PubMed Web of Science ®Google Scholar
• Bell SJ, Whitehead P, Aslani P, McLachlan AJ, Chen TFDrug-related problems in the community settingClin Drug Invest2006267415425 10.2165/00044011-200626070-00003
   PubMed Web of Science ®Google Scholar
• National Mental Health Commission. Equally Well Consensus Statement: Improving the physical health and wellbeing of people living with mental illness in Australia Sydney: National Mental Health Commission; 2016 [cited: 20 October 2022]. Available from: https://www.equallywell.org.au/wp-content/uploads/2018/12/Equally-Well-National-Consensus-Booklet-47537.pdf.
   Google Scholar
• Wheeler A, Mey A, Kelly F, Hattingh L, Davey A. Education and training for community pharmacists in mental health practice: how to equip this workforce for the future. J Mental Health Training Educ Pract. 2014;9(3). https://doi.org/10.1108/JMHTEP-09-2013-0030.
   Google Scholar
• O'Reilly C, Bell S, Kelly P, Chen TExploring the relationship between mental health stigma, knowledge and provision of pharmacy services for consumers with schizophreniaRes Social Adm Pharm2015113e101e109 10.1016/j.sapharm.2013.04.006 23632161
   PubMed Web of Science ®Google Scholar
• Wheeler AJ, Spinks J, Kelly F, Ware RS, Vowles E, Stephens M, et al.Protocol for a feasibility study of an Indigenous Medication Review Service (IMeRSe) in AustraliaBMJ Open2018811 10.1136/bmjopen-2018-026462 30391923 6231589
   PubMed Web of Science ®Google Scholar
• Wheeler AJ, O'Reilly CL, El-Den S, Byrnes J, Ware RS, McMillan SSBridging the gap between physical and mental illness in community pharmacy (PharMIbridge): protocol for an Australian cluster randomised controlled trialBMJ Open2020107 10.1136/bmjopen-2020-039983 32709657 7380878
   PubMedGoogle Scholar
• Wheeler AJ, Hu J, Tadakamadla SK, Hall K, Miller A, Kelly FDevelopment and feasibility testing of a training programme for community pharmacists to deliver a culturally responsive medication review interventionPilot Feasibility Stud20228151 10.1186/s40814-022-01006-2 35241184 8892753
   PubMedGoogle Scholar
• McMillan SS, El-Den S, O’Reilly CL, Roennfeldt H, Theodorus T, Chapman J, et al.A training programme for community pharmacists to support people living with severe and persistent mental illness: intervention mapping in the context of a pandemicHealth Educ J2022 10.1177/00178969221130461
   Web of Science ®Google Scholar
• Dingwall KM, Puszka S, Sweet M, Nagel T“like drawing into sand”: acceptability, feasibility, and appropriateness of a new e-mental health resource for service providers working with Aboriginal and Torres Strait Islander peopleAust Psychol20155016069 10.1111/ap.12100
   Web of Science ®Google Scholar
• Ashoorian DM, Davidson RM, Rock DJ, Dragovic M, Clifford RMConstruction and validation of the My Medicines and Me Questionnaire for assessment of the self-reported side effects of psychotropic medicationInt Clin Psychopharmacol2015304224229 10.1097/yic.0000000000000072 25852030
   PubMed Web of Science ®Google Scholar
• Williams M, Peterson GM, Tenni PC, Bindoff IK, Stafford ACDOCUMENT: a system for classifying drug-related problems in community pharmacyInt J Clin Pharm20123414352 10.1007/s11096-011-9583-1 22101425
   PubMed Web of Science ®Google Scholar
• Pharmaceutical Society of Australia. Guidelines for pharmacists performing clinical interventions. Canberra; 2018.
   Google Scholar
• Pharmacy Programs Administrator. Clinical interventions program ceasing Melbourne: Pharmacy Programs Administrator; 2022 [cited: 20 January 2023]. Available from: https://www.ppaonline.com.au/ci-program-ceasing#:~:text=Under%20the%20newly%20signed%20Seventh,cease%20from%201%20July%202020.
   Google Scholar
• de Dassel JL, Ralph AP, Cass AA systematic review of adherence in Indigenous Australians: an opportunity to improve chronic condition managementBMC Health Serv Res2017171845 10.1186/s12913-017-2794-y 29282117 5745645
   PubMedGoogle Scholar
• Walke E, Barclay L, Longman JScoping review—what do we know about Aboriginal peoples’ use of dose administration aids?Health Promot J Aust202233S1117127 10.1002/hpja.577
   PubMedGoogle Scholar
• Saxby K, Byrnes J, de New SC, Nghiem S, Petrie DDoes affirmative action reduce disparities in healthcare use by Indigenous peoples? Evidence from Australia's Indigenous Practice Incentives ProgramHealth Econ2023 10.1002/hec.4645 36609870
   PubMed Web of Science ®Google Scholar
• Semahegn A, Torpey K, Manu A, Assefa N, Tesfaye G, Ankomah APsychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysisSyst Rev20209117 10.1186/s13643-020-1274-3 31948489 6966860
   PubMed Web of Science ®Google Scholar
• Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GEWhat is polypharmacy? A systematic review of definitionsBMC Geriatr2017171110 10.1186/s12877-017-0621-2
   PubMedGoogle Scholar
• Zhao Y, You J, Wright J, Guthridge SL, Lee AHHealth inequity in the Northern Territory, AustraliaInt J Equity Health201312179 10.1186/1475-9276-12-79 24034417 3847185
   PubMedGoogle Scholar
• Australian Institute of Health and Welfare. Aboriginal and Torres Strait Islander Health Performance Framework: summary report 2023 Canberra: AIHW; 2023 [cited: February 14, 2023]. Available from: https://www.indigenoushpf.gov.au/getattachment/d396ed0d-9347-4de6-8b41-ff56bf3dfa18/2023-ihpf-summary-report.pdf.
   Google Scholar
• Hu J, McMillan SS, Theodoros T, Collins JC, El-Den S, O’Reilly CL, et al.Psychotropic medication use in people living with severe and persistent mental illness in the Australian community: a cross-sectional studyBMC Psychiatry2022221705 10.1186/s12888-022-04324-0 36380352 9667665
   PubMed Web of Science ®Google Scholar
• Ashoorian D. My Medicines & Me Questionnaire (M3Q): A side effect questionnaire for mental health medications 2014 [cited: 27 January 2023]. Available from: https://www.chiefpsychiatrist.wa.gov.au/wp-content/uploads/2016/10/M3Q_Fillable.pdf.
   Google Scholar
• Williams M, Peterson GM, Tenni PC, Bindoff IK, Curtain C, Hughes J, et al.Drug-related problems detected in Australian community pharmacies: the PROMISe TrialAnn Pharmacother201145910671076 10.1345/aph.1Q138 21878658
   PubMed Web of Science ®Google Scholar
• Wang X, Yang J, Yu X, Wang Z, Wang H, Liu LCharacterization of drug-related problems and associated factors in ambulatory patients in ChinaJ Clin Pharm Ther202045510581065 10.1111/jcpt.13161 32516504
   PubMed Web of Science ®Google Scholar
• Granas AG, Berg C, Hjellvik V, Haukereid C, Kronstad A, Blix HS, et al.Evaluating categorisation and clinical relevance of drug-related problems in medication reviewsPharm World Sci2010323394403 10.1007/s11096-010-9385-x 20407926
   PubMedGoogle Scholar
• Hugo Centre for Population and Migration Studies. Pharmacy accessibility in Australia Adelaide: The University of Adelaide; 2018 [cited: 27 January 2023]. Available from: https://able.adelaide.edu.au/hugo-centre/news/list/2018/10/23/pharmacy-accessibility-in-australia.
   Google Scholar
• Australian Government Department of Health and Aged Care. Modified Monash Model: Australian Government; 2021 [cited: 20 January 2023]. Available from: https://www.health.gov.au/health-topics/rural-health-workforce/classifications/mmm.
   Google Scholar